Cardiovascular Diseases

Higher TMAO Levels Linked to Greater Risk of Abdominal Aortic Aneurysm

Higher blood levels of the gut microbiome-derived metabolite trimethylamine N-oxide (TMAO) were independently associated with an increased risk of developing abdominal aortic aneurysms (AAAs) and experiencing serious AAA-related events in apparently healthy older adults. Researchers measured plasma TMAO levels in 4,442 community-dwelling adults aged 65 years or older from the US Cardiovascular Health Study and followed them prospectively with ultrasound screening. Higher baseline TMAO levels were associated with larger infrarenal aortic diameter and a greater likelihood of AAA. During a median follow-up of 12.2 years (54,402 person-years), 79 participants experienced major AAA events, including aneurysm repair, rupture, or AAA-related death. After adjusting for traditional cardiovascular risk factors, kidney function, socioeconomic status, and cardiometabolic lifestyle factors, elevated TMAO remained independently associated with a significantly higher risk of adverse AAA outcomes, whether analyzed as a continuous measure, by tertiles, or using a clinical threshold of ≥6.2 μM. These findings identify TMAO as a novel risk factor for AAA and suggest it may represent a potential therapeutic target for preventing AAA development and progression. Source: https://academic.oup.com/eurheartj/

hyangiu

Recent Posts

Intensive BP Control Reduces Cardiovascular Events After Ischemic Stroke

Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…

20 hours ago

No Significant Reduction in Major Cardiovascular Events with Intensive BP Lowering in T2D

In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…

20 hours ago

Stopping Statins Noninferior to Continuing Them in Older Adults without Known CVD

Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuing…

22 hours ago

Ziltivekimab and Pelacarsen Show No Clinical Benefit Despite Effective Biomarker Lowering

Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an…

2 days ago

Cold Drives Heart Failure Hospitalizations in Older US Adults

Among US Medicare beneficiaries, colder ambient temperatures were associated with increased heart failure hospitalizations while…

6 days ago

No Significant Difference Between Initial CTO-PCI and No CTO-PCI Strategies in 10-Year Follow-Up

In the 10-year extended follow-up of the DECISION-CTO trial, an initial strategy of percutaneous coronary…

6 days ago

This website uses cookies.